{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Double+Blind&page=98",
    "query": {
      "condition": "Double Blind",
      "page": 98
    },
    "page_size": 10
  },
  "pagination": {
    "page": 98,
    "page_size": 10,
    "total_count": 18305,
    "total_pages": 1831,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Double+Blind&page=99&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Double+Blind&page=97&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T07:55:56.567Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00042575",
      "title": "Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Duloxetine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2002-06",
      "completion_date": "2002-08",
      "has_results": false,
      "last_update_posted_date": "2006-07-19",
      "last_synced_at": "2026-11-20T07:55:56.567Z",
      "location_count": 9,
      "location_summary": "Trumbull, Connecticut • Lafayette, Indiana • Gaithersburg, Maryland + 6 more",
      "locations": [
        {
          "city": "Trumbull",
          "state": "Connecticut"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Gaithersburg",
          "state": "Maryland"
        },
        {
          "city": "Belmont",
          "state": "Massachusetts"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00042575"
    },
    {
      "nct_id": "NCT07881757",
      "title": "A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Apnea",
        "Sleep Disorders",
        "Overweight and/or Obesity"
      ],
      "interventions": [
        {
          "name": "Berobenatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2026-10-19",
      "completion_date": "2028-07-20",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-20T07:55:56.567Z",
      "location_count": 4,
      "location_summary": "Cullman, Alabama • Bradenton, Florida • Maplewood, Minnesota + 1 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Maplewood",
          "state": "Minnesota"
        },
        {
          "city": "Tomball",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07881757"
    },
    {
      "nct_id": "NCT00067457",
      "title": "Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Irritable Colon",
        "Irritable Bowel Syndrome (IBS)"
      ],
      "interventions": [
        {
          "name": "alosetron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 700,
      "start_date": "2003-06",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2015-04-16",
      "last_synced_at": "2026-11-20T07:55:56.567Z",
      "location_count": 190,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Pell City",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00067457"
    },
    {
      "nct_id": "NCT04532957",
      "title": "A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "KBP-7072",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "KBP Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-08-11",
      "completion_date": "2020-10-15",
      "has_results": false,
      "last_update_posted_date": "2024-02-23",
      "last_synced_at": "2026-11-20T07:55:56.567Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04532957"
    },
    {
      "nct_id": "NCT01766401",
      "title": "Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Vilazadone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 402,
      "start_date": "2013-01-31",
      "completion_date": "2014-01-29",
      "has_results": true,
      "last_update_posted_date": "2019-12-18",
      "last_synced_at": "2026-11-20T07:55:56.567Z",
      "location_count": 30,
      "location_summary": "Arcadia, California • Beverly Hills, California • Encino, California + 26 more",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01766401"
    },
    {
      "nct_id": "NCT00123201",
      "title": "Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Migraine With Aura",
        "Migraine Without Aura"
      ],
      "interventions": [
        {
          "name": "Dronabinol MDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Solvay Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": null,
      "start_date": "2005-09",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2015-01-16",
      "last_synced_at": "2026-11-20T07:55:56.567Z",
      "location_count": 29,
      "location_summary": "Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00123201"
    },
    {
      "nct_id": "NCT03551730",
      "title": "Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "PRT064445/Enoxaparin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo/Enoxaparin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Portola Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 27,
      "start_date": "2012-12",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2023-02-22",
      "last_synced_at": "2026-11-20T07:55:56.567Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03551730"
    },
    {
      "nct_id": "NCT00948428",
      "title": "Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Actinic Keratoses"
      ],
      "interventions": [
        {
          "name": "imiquimod",
          "type": "DRUG"
        },
        {
          "name": "Aldara™",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 462,
      "start_date": "2008-05",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2020-09-04",
      "last_synced_at": "2026-11-20T07:55:56.567Z",
      "location_count": 20,
      "location_summary": "Hot Springs, Arkansas • Fresno, California • San Diego, California + 17 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00948428"
    },
    {
      "nct_id": "NCT00977665",
      "title": "Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple System Atrophy"
      ],
      "interventions": [
        {
          "name": "rasagiline mesylate",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 174,
      "start_date": "2009-12",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2015-02-26",
      "last_synced_at": "2026-11-20T07:55:56.567Z",
      "location_count": 15,
      "location_summary": "Irvine, California • La Jolla, California • Sunnyvale, California + 12 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00977665"
    },
    {
      "nct_id": "NCT04007367",
      "title": "A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "SAGE-217",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 53,
      "start_date": "2019-08-06",
      "completion_date": "2020-01-06",
      "has_results": true,
      "last_update_posted_date": "2023-11-29",
      "last_synced_at": "2026-11-20T07:55:56.567Z",
      "location_count": 46,
      "location_summary": "Bentonville, Arkansas • Bellflower, California • Garden Grove, California + 40 more",
      "locations": [
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04007367"
    }
  ]
}